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Plasmodium vivax malaria remains a significant health
burden in endemic areas like South East Asia, Central
and South America. P. vivax infections are characterized
by relapses of malaria caused by persistent liver stages
of the parasite (hypnozoites) which are not present in
P. falciparum infections. Currently, the only approved
treatment option for the radical cure of P. vivax malaria
is the 8-aminoquinoline, primaquine. However the long
treatment course (two weeks) and severe side effects
(hemolytic anemia in G6PD-deficeint patients) highlights
the need for new chemical classes of drugs.
Currently the discovery of new anti-hypnozoite drugs is
limited to testing in the P. cynomolgi rhesus monkey
model. However recently developed assays that allow for
the testing of new chemical entities on the parasite liver-
stages (schizonts) and sexual stages (gametocytes) could
be leveraged to identify dual acting compounds with
potental anti-hypnozoite activity. In addition, compounds
which target more than one stage in the Plasmodium life-
cycle would be highly valued and compliment the current
arsenal of antimalarial drugs.
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